Resistance Testing for Integrase Strand Transfer Inhibitors in Naive, Human Immunodeficiency Virus-infected Individuals.

[1]  R. Shafer,et al.  Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Huldrych F. Günthard,et al.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel , 2018, JAMA.

[3]  V. Calvez,et al.  Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen , 2018, The Journal of antimicrobial chemotherapy.

[4]  C. Charpentier,et al.  Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations , 2018, Viruses.

[5]  R. Walensky,et al.  Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus? , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  C. Fraser,et al.  Recent trends and patterns in HIV‐1 transmitted drug resistance in the United Kingdom , 2016, HIV medicine.

[7]  J. Miro,et al.  Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection , 2017, The Journal of antimicrobial chemotherapy.

[8]  A. Zoufaly,et al.  Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013 , 2017, Infection.

[9]  M. Poljak,et al.  Primary resistance to integrase strand-transfer inhibitors in Europe. , 2015, The Journal of antimicrobial chemotherapy.